vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.

Valens Semiconductor Ltd. is the larger business by last-quarter revenue ($17.3M vs $13.3M, roughly 1.3× OCULAR THERAPEUTIX, INC). Valens Semiconductor Ltd. runs the higher net margin — -42.2% vs -488.0%, a 445.7% gap on every dollar of revenue. On growth, Valens Semiconductor Ltd. posted the faster year-over-year revenue change (8.1% vs -22.4%). Valens Semiconductor Ltd. produced more free cash flow last quarter ($-4.9M vs $-57.1M).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...

OCUL vs VLN — Head-to-Head

Bigger by revenue
VLN
VLN
1.3× larger
VLN
$17.3M
$13.3M
OCUL
Growing faster (revenue YoY)
VLN
VLN
+30.5% gap
VLN
8.1%
-22.4%
OCUL
Higher net margin
VLN
VLN
445.7% more per $
VLN
-42.2%
-488.0%
OCUL
More free cash flow
VLN
VLN
$52.1M more FCF
VLN
$-4.9M
$-57.1M
OCUL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
OCUL
OCUL
VLN
VLN
Revenue
$13.3M
$17.3M
Net Profit
$-64.7M
$-7.3M
Gross Margin
88.0%
63.0%
Operating Margin
-526.5%
-46.4%
Net Margin
-488.0%
-42.2%
Revenue YoY
-22.4%
8.1%
Net Profit YoY
-33.6%
29.3%
EPS (diluted)
$-0.27
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
VLN
VLN
Q4 25
$13.3M
Q3 25
$14.5M
$17.3M
Q2 25
$13.5M
$17.1M
Q1 25
$10.7M
$16.8M
Q4 24
$17.1M
Q3 24
$15.4M
$16.0M
Q2 24
$16.4M
$13.6M
Q1 24
$14.8M
Net Profit
OCUL
OCUL
VLN
VLN
Q4 25
$-64.7M
Q3 25
$-69.4M
$-7.3M
Q2 25
$-67.8M
$-7.2M
Q1 25
$-64.1M
$-8.3M
Q4 24
$-48.4M
Q3 24
$-36.5M
$-10.4M
Q2 24
$-43.8M
$-8.9M
Q1 24
$-64.8M
Gross Margin
OCUL
OCUL
VLN
VLN
Q4 25
88.0%
Q3 25
87.8%
63.0%
Q2 25
85.6%
63.5%
Q1 25
88.2%
62.9%
Q4 24
92.8%
Q3 24
89.9%
56.4%
Q2 24
90.8%
61.4%
Q1 24
91.0%
Operating Margin
OCUL
OCUL
VLN
VLN
Q4 25
-526.5%
Q3 25
-472.3%
-46.4%
Q2 25
-502.6%
-43.3%
Q1 25
-597.5%
-56.2%
Q4 24
-296.1%
Q3 24
-298.2%
-76.3%
Q2 24
-265.1%
-69.2%
Q1 24
-214.0%
Net Margin
OCUL
OCUL
VLN
VLN
Q4 25
-488.0%
Q3 25
-477.3%
-42.2%
Q2 25
-503.9%
-42.1%
Q1 25
-598.7%
-49.4%
Q4 24
-283.3%
Q3 24
-236.6%
-64.6%
Q2 24
-266.3%
-65.2%
Q1 24
-438.9%
EPS (diluted)
OCUL
OCUL
VLN
VLN
Q4 25
$-0.27
Q3 25
$-0.38
$-0.07
Q2 25
$-0.39
$-0.07
Q1 25
$-0.38
$-0.08
Q4 24
$-0.25
Q3 24
$-0.22
$-0.10
Q2 24
$-0.26
$-0.08
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
VLN
VLN
Cash + ST InvestmentsLiquidity on hand
$737.1M
$93.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$654.3M
$108.8M
Total Assets
$808.1M
$136.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
VLN
VLN
Q4 25
$737.1M
Q3 25
$344.8M
$93.5M
Q2 25
$391.1M
$102.7M
Q1 25
$349.7M
$112.5M
Q4 24
$392.1M
Q3 24
$427.2M
$133.1M
Q2 24
$459.7M
$105.9M
Q1 24
$482.9M
Stockholders' Equity
OCUL
OCUL
VLN
VLN
Q4 25
$654.3M
Q3 25
$258.2M
$108.8M
Q2 25
$305.9M
$116.5M
Q1 25
$265.9M
$128.6M
Q4 24
$315.3M
Q3 24
$352.0M
$147.0M
Q2 24
$377.7M
$153.5M
Q1 24
$408.0M
Total Assets
OCUL
OCUL
VLN
VLN
Q4 25
$808.1M
Q3 25
$410.9M
$136.7M
Q2 25
$451.3M
$144.8M
Q1 25
$405.9M
$154.6M
Q4 24
$457.9M
Q3 24
$490.4M
$171.9M
Q2 24
$517.1M
$175.8M
Q1 24
$538.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
VLN
VLN
Operating Cash FlowLast quarter
$-54.2M
$-4.7M
Free Cash FlowOCF − Capex
$-57.1M
$-4.9M
FCF MarginFCF / Revenue
-430.9%
-28.5%
Capex IntensityCapex / Revenue
21.4%
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M
$-11.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
VLN
VLN
Q4 25
$-54.2M
Q3 25
$-50.7M
$-4.7M
Q2 25
$-55.2M
$-211.0K
Q1 25
$-44.7M
$-7.6M
Q4 24
$-39.4M
Q3 24
$-36.6M
$3.0M
Q2 24
$-24.8M
$-225.0K
Q1 24
$-33.9M
Free Cash Flow
OCUL
OCUL
VLN
VLN
Q4 25
$-57.1M
Q3 25
$-56.7M
$-4.9M
Q2 25
$-56.5M
$-330.0K
Q1 25
$-46.6M
$-8.0M
Q4 24
$-39.6M
Q3 24
$-36.6M
$2.2M
Q2 24
$-25.5M
$-460.0K
Q1 24
$-34.1M
FCF Margin
OCUL
OCUL
VLN
VLN
Q4 25
-430.9%
Q3 25
-390.0%
-28.5%
Q2 25
-419.7%
-1.9%
Q1 25
-435.6%
-47.3%
Q4 24
-232.0%
Q3 24
-237.6%
14.0%
Q2 24
-155.4%
-3.4%
Q1 24
-231.1%
Capex Intensity
OCUL
OCUL
VLN
VLN
Q4 25
21.4%
Q3 25
41.2%
1.6%
Q2 25
9.3%
0.7%
Q1 25
18.1%
2.1%
Q4 24
1.2%
Q3 24
0.6%
4.5%
Q2 24
4.5%
1.7%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons